SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 18th, 2020 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 16, 2020, between Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
ACTINIUM PHARMACEUTICALS, INC., ISSUER AND [TRUSTEE], TRUSTEEIndenture • April 10th, 2014 • Actinium Pharmaceuticals, Inc. • Blank checks • New York
INDENTURE, dated as of [·], 20__, among ACTINIUM PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), and [TRUSTEE], as trustee (the "Trustee"):
Form of Warrant PRE-FUNDED COMMON STOCK PURCHASE WARRANT ACTINIUM PHARMACEUTICALS, INC.Warrant Agreement • April 24th, 2020 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PRE-FUNDED COMMON STOCK PURCHASE WARRANT ACTINIUM PHARMACEUTICALS, INC.Pre-Funded Common Stock Purchase Warrant • June 18th, 2020 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
ACTINIUM PHARMACEUTICALS, INC. AND ___________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ___________Preferred Stock Warrant Agreement • April 10th, 2014 • Actinium Pharmaceuticals, Inc. • Blank checks • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this "Agreement"), dated as of [•], between ACTINIUM PHARMACEUTICALS, INC., a Delaware corporation (the "Company") and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the "Warrant Agent").
ACTINIUM PHARMACEUTICALS, INC. AND ___________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ___________Warrant Agreement • April 10th, 2014 • Actinium Pharmaceuticals, Inc. • Blank checks • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this "Agreement"), dated as of [•], between ACTINIUM PHARMACEUTICALS, INC., a Delaware corporation (the "Company") and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the "Warrant Agent").
Common Stock, par value $0.001 per share Warrants to Purchase Shares of Common Stock Underwriting AgreementUnderwriting Agreement • February 6th, 2015 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer the Lock-Up Securities without the prior written consent of the Representative, provided that (1) the Representative receives a signed lock-up agreement for the balance of the lockup period from each donee, trustee, distributee, or transferee, as the case may be, (2) any such transfer shall not involve a disposition for value, (3) such transfers are not required to be reported with the Securities and Exchange Commission in accordance with the Securities Exchange Act of 1934, as amended the (“Exchange Act”) under Section 16 or otherwise, and (4) neither the undersigned nor any donee, trustee, distributee or transferee, as the case may be, otherwise voluntarily effects any public filing or report or other public notice regarding such transfers:
Actinium Pharmaceuticals, Inc. and Action Stock Transfer Corporation, as Warrant Agent Warrant Agency Agreement Dated as of [ ] WARRANT AGENCY AGREEMENTWarrant Agency Agreement • February 15th, 2018 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of [ ] (“Agreement”), between Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Action Stock Transfer Corporation (the “Warrant Agent”).
ACTINIUM PHARMACEUTICALS, INC. Common Stock (par value $0.001 per share) Amended and Restated At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • March 15th, 2019 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
PURCHASE AGREEMENTPurchase Agreement • October 18th, 2018 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • Illinois
THIS PURCHASE AGREEMENT (the “Agreement”), dated as of October 18, 2018 (the “Execution Date”), is entered into by and between ACTINIUM PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof.
ACTINIUM PHARMACEUTICALS, INC. AND __________________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF _________________Warrant Agreement • April 10th, 2014 • Actinium Pharmaceuticals, Inc. • Blank checks • New York
THIS COMMON STOCK WARRANT AGREEMENT (this "Agreement"), dated as of [•], between ACTINIUM PHARMACEUTICALS, INC., a Delaware corporation (the "Company") and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the "Warrant Agent").
FORM OF WARRANT] ACTINIUM PHARMACEUTICALS, INC. Warrant To Purchase Common StockWarrant Agreement • July 28th, 2017 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Actinium Pharmaceuticals, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after August [ ], 2017 (the “Initial Exercisability Date”), but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), ______________ (_____________)1 fully paid non-assessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this “Warrant”), shall have th
ACTINIUM PHARMACEUTICALS, INC.Dealer-Manager Agreement • February 15th, 2018 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
The following (this “Agreement”) will confirm our agreement relating to the proposed rights offering (the “Rights Offering”) to be undertaken by Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to which the Company will distribute to holders of record of its common stock, par value $0.001 per share (the “Common Stock”) and to holders of certain of its outstanding warrants to purchase approximately 21,608,333 shares of Common Stock, issued on August 2, 2017 and February 11, 2015 (the “Participating Warrants”), who are entitled to participate in such offering pursuant to the terms of such warrants, subscription rights (the “Rights”) to subscribe for up to an aggregate of 35,714,285 units (the “Units”), each Unit consisting of (i) one share of Common Stock (the “Rights Shares”), (ii) 0.25 Series A Warrants (the “Series A Warrants”), with each whole Series A Warrant representing the right to purchase one share of Common Stock at an exercise price of $0.90 pe
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 18th, 2018 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • Illinois
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 18, 2018, is entered into by and between ACTINIUM PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
At-the-Market Issuance Sales AgreementAt-the-Market Issuance Sales Agreement • March 24th, 2014 • Actinium Pharmaceuticals, Inc. • Blank checks • New York
Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:
Amended and Restated Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • June 29th, 2022 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Actinium Pharmaceuticals, Inc. 21,500,000 Shares of Common Stock and Warrants to Purchase up to 18,275,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 28th, 2017 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”) proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of (i) 21,500,000 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), and (ii) warrants (the “Warrants”) to purchase up to an aggregate of 18,275,000 shares of Common Stock (the “Warrant Shares”). Each Share is being sold together with .85 of a Warrant to purchase one Warrant Share. The Shares, the Warrants and the Warrant Shares are collectively referred to as the “Securities”. The Shares and the Warrants will be issued separately, but will be purchased together in the offering. The respective amounts of the Securities to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto.
INDEMNIFICATION AGREEMENTIndemnification Agreement • May 1st, 2018 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into and effective on the date set forth below, by and between Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and Jeffrey W. Chell (“Indemnitee”).
SHARE EXCHANGE AGREEMENT BY AND AMONG ACTINIUM PHARMACEUTICALS, INC. AND ACTINIUM CORPORATION AND THE SHAREHOLDERS OF ACTINIUM CORPORATION Dated as of: August 22, 2013Share Exchange Agreement • August 22nd, 2013 • Actinium Pharmaceuticals, Inc. • Blank checks • New York
Acquiree Shareholder Total Acquiree Options and Warrants Held Prior to the Closing Acquiror Options and Warrants to be Issued at the Closing Total
Actinium Pharmaceuticals, Inc. Common Stock, par value $0.001 per share, and Pre-Funded Warrants to Purchase Common Stock Underwriting AgreementUnderwriting Agreement • April 24th, 2020 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom H.C. Wainwright & Co., LLC is acting as representative (the “Representative” or “you”), (A) an aggregate of (i) 100,833,333 shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”) of the Company and (ii) pre-funded warrants to purchase up to 82,500,001 shares of Common Stock in the form set forth on Exhibit A (the “Warrants” and, together with the Firm Shares, the “Firm Securities”), and (B) subject to the option described in Sections 2 and 4 hereof granted by the Company to the Underwriters, all or any part of 27,500,000 additional shares of Common Stock to cover over-allotments, if any (the “Option Shares” and, together with the Firm Shares, the “Shares”). The shares of Common Stock underlying the Warrants are herein called
UNIT PURCHASE AGREEMENTUnit Purchase Agreement • January 31st, 2014 • Actinium Pharmaceuticals, Inc. • Blank checks • New York
UNIT PURCHASE AGREEMENT (this “Agreement”) made as of the date set forth on the signature page hereof between Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the subscriber(s) identified on Exhibit A annexed hereto (the “Subscriber”).
Actinium Pharmaceuticals, Inc. CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENTConfidential Information and Invention Assignment Agreement • May 1st, 2018 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT (this “Agreement”) is made and entered into and effective on the date set forth below, by and between Actinium Pharmaceuticals, Inc., a Delaware corporation, or any of its current or future subsidiaries, affiliates, successors or assigns (collectively, the “Company”) and Jeffrey W. Chell, M.D.
August 6, 2015Employment Agreement • August 7th, 2015 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to provide you with this amendment and restatement of your employment agreement (the “Agreement”) for the position of Chief Executive Officer.
ACTINIUM PHARMACEUTICALS, INC. 8,000,000 Shares Common Stock ($0.001 par value) Underwriting Agreement Underwriting AgreementUnderwriting Agreement • September 29th, 2016 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
BY AND AMONG ACTINIUM PHARMACEUTICALS, INC. AND THE INVESTORS PARTY HERETO October __, 2012Unit Investor Rights Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks • New York
THIS 2012 UNIT INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of October__, 2012, by and among Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the persons identified on Exhibit A hereto (the “Investors”), and the Placement Agent (defined below).
SUBSCRIPTION AGREEMENTSubscription Agreement • June 5th, 2015 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
August 12, 2020Employment Agreement • August 14th, 2020 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to provide you with this contract (the “Agreement”) related to your position as Chief Financial Officer of the Company. This Agreement replaces and supersedes the employment agreement between you and the Company dated August 8, 2018.
SEPARATION AND SETTLEMENT AGREEMENT BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND DRAGAN CICICSeparation and Settlement Agreement • August 4th, 2017 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Separation and Settlement Agreement (“Agreement”), dated as of May 12, 2017 (the “Effective Date”), is made by and between Actinium Pharmaceuticals, Inc., a Delaware company (“Actinium” or the “Company”), and Dragan Cicic (“Employee”).
INVESTORS’ RIGHTS AGREEMENT BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND MEMORIAL SLOAN KETTERING CANCER CENTERInvestors’ Rights Agreement • December 24th, 2015 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 21st day of December, 2015, by and between Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Memorial Sloan Kettering Cancer Center, a New York not-for-profit corporation (“MSKCC”).
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • August 4th, 2017 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations
This Agreement amends and restates in its entirety that certain Office Space License Agreement, dated as of March 10, 2016 and effective as of January 1, 2016, between Relmada and Actinium (the “Original Agreement”) for office space within the Premises. This Agreement is intended to and does completely amend and restate the Original Agreement.
ContractAssignment and Consent Agreement • August 4th, 2017 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS ASSIGNMENT AND CONSENT AGREEMENT (this “Agreement”), made as of the 6th day of June, 2017, between 275 MADISON AVENUE RPW 1 LLC and 275 MADISON AVENUE RPW 2 LLC, having an office in care of RPW Group, Inc., 800 Westchester Avenue, Rye Brook, New York 10573, hereinafter referred to collectively as the “Owner,” RELMADA THREAPEUTICS, INC., having an office at 275 Madison Avenue, Suite 702, New York, New York 10016, hereinafter referred to as the “Assignor,” and ACTINIUM PHARMACEUTICALS, INC., having an office at 275 Madison Avenue, Suite 702, New York, New York 10016, hereinafter referred to as the “Assignee.”
Project Agreement Number: 1 Aptiv Project Number: ACTI-1903Project Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks
This Project Agreement is made and entered into on September 30, 2011, the Effective Date, by and between Actinium Pharmaceuticals, Inc., with offices at 391 Lafayette Street, Newark, NJ 07105 (hereinafter referred to as "Client") and Aptiv Solutions, Inc., together with its Affiliates, with offices at 1925 Isaac Newton Square, Suite 100, Reston, Virginia 20190 (hereinafter referred to as "Aptiv").
TRANSACTION MANAGEMENT AGREEMENTTransaction Management Agreement • September 30th, 2013 • Actinium Pharmaceuticals, Inc. • Blank checks • New York
This Transaction Management ("Agreement") is made as of the 9th day of May, 2011 (“Effective Date”) by and between AmerAsia Capital Group LLC (the “Transaction Manager”), a Delaware Limited Liability Company, with principal office at 244 Fifth Avenue, 2nd Floor, Suite S217, New York, NY 10001 and Actinium Pharmaceuticals Inc. (the “Company”) a Delaware corporation, with principal office at 391 Lafayette Street, Newark, NJ 07105.
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks
THIS CLINICAL TRIAL AGREEMENT ("Agreement") is made by and between Fred Hutchinson Cancer Research Center, a nonprofit corporation having a principal place of business at 1100 Fairview Avenue N., J5-110, Seattle, Washington 98109 ("Site") and Actinium Pharmaceuticals, Inc. with an address of 25B Hanover Road, Florham Park, New Jersey 07932 ("Actinium"). This Agreement is entered into this July 19, 2012.
LICENSE AGREEMENTLicense Agreement • January 4th, 2013 • Cactus Ventures, Inc. • Blank checks • Washington
This License Agreement (the "Agreement") effective as of the Effective Date, by and between Fred Hutchinson Cancer Research Center, a research institution organized as a nonprofit corporation under the laws of the state of Washington, having its principal offices at 1100 Fairview Avenue North, Seattle, Washington 98108, USA ("FHCRC") and Actinium Pharmaceuticals, Inc., a Delaware corporation, with principal offices at 391 Lafayette Street, Newark, NJ 07105 ("Company").
